Possible risk factors associated with relapse in patients treated with neoadjuvant chemohormonal therapy for high risk prostate cancer

Open Prostate Cancer Journal

Volumn 4, Issue , 2011, Pages 6-13

  Bhatt, R S ^a   Werner, L ^a   Regan, M M ^a   Yannucci, J ^b   Ko, Y J ^c   Wang, H Y ^a   Rosen, S ^a   Genega, E ^a   Morrissey, M E ^a   Duggan, S ^a   Vazquez, C ^a   Sanda, M ^a   Dewolf, W ^a   Balk, S ^a   Yuan, X ^a   Bubley, G J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GENERAL ELECTRIC COMPANY   (United States)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

High risk prostate cancer; Neoadjuvant; Sox 9

Indexed keywords

BICALUTAMIDE; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR SOX9; TUMOR MARKER; WARFARIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG EMBOLISM; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SALVAGE THERAPY; SIDE EFFECT; TISSUE MICROARRAY; TUMOR BIOPSY;

EID: 79955068168     PISSN: None     EISSN: 18768229     Source Type: Journal    
DOI: 10.2174/1876822901104010006     Document Type: Article

References (28)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131.
2. Kattan MW, Eastham JA, Stapleton AM, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766.
3. Pilepich, MV, Winter, K, Lawton, CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285.
4. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103.
5. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791.
6. Gleave ME, Goldenberg L, Chin JL, et al. Randomized comparative study of 3 versus 8 months of neoadjuvant hormone therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500-507.
7. Shelly MD, Kumar S, Wilt T, et al. A systematic review of metaanalysis of randomized trials of neo-adjuvant hormone therapy for localized and locally advanced prostate carcinoma Cancer Treat Rev 2009; 35: 9.
8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513.
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502.
10. Clark PE, Peereboom DM, Dreicer R, et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001; 57: 281.
11. Konety BR, Eastham JA, Reuter VE, et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 709.
12. Mathew P, Pisters LL, Wood CG, et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009; 181: 81.
13. Pettaway, CA, Pisters, LL, Troncoso P, et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000; 18:1050.
14. Chi KN, Chin JL, Winquist E, et al. Multicenter Phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008; 180: 565.
15. Prayer-Galetti T, Sacco E, Pagano F, et al. Long-term follow-up of a neoadjuvant chemohormonal trial before radical prostatecotmy in patients with non-metastatic high-risk prostate cancer. BJU 2007; 100: 274.
16. Sella A, Zisman A, Kovel S, et al. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Oncology 2007; 71: 323.
17. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 2003; 61:774.
18. Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Can Res 2005; 11: 4905.
19. Wang H, McKnight N, Zhang T, et al. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression Cancer Res 2007; 67: 528.
20. Thomsen MK, Ambroisine L, Wynn S, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010; 70(3): 979-87.
21. Wang H, Leav I, Ibargi S, et al. SOX9 is expressed in human fetal prosate epithelium and enhances prostate cancer invasion. Cancer Res 2008; 68: 1625.
22. Eastham JA, Kelly WK, Grossfield GD, et al. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high risk localized disease. Urology 2003; 62: 52.
23. Soloway MS, Areek P, Sharifi K, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002; 167: 112.
24. Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11: 5233.
25. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009; 181: 1672.
26. Van Poppel H, De Ridder D, Elgamal AA, et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group. J Urol 1995; 154: 429.
27. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer reduces the risk of metastases and improves long-term survival L long-term followup of a randomized clinical trial. J Urol 2009; 181: 956.
28. Attard G, Reid AH, Olmost D, et al. Anti-tumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009; 69: 4937.